Lv41
560 积分 2023-06-19 加入
UT-7/EPO细胞培养条件的优化及复壮
8小时前
待确认
Establishment and characterization of an erythropoietin-dependent subline, UT-7/Epo, derived from human leukemia cell line, UT-7
9小时前
已关闭
Establishment and characterization of an erythropoietin-dependent subline, UT-7/Epo, derived from human leukemia cell line, UT-7
9小时前
已关闭
Assay development considerations to improve drug tolerance in direct competitive ligand binding neutralizing antibody assays, pretreatment strategies
6个月前
已完结
Development and Validation of a Cell-Based Binding Neutralizing Antibody Assay for an Antibody–Drug Conjugate
6个月前
已完结
Antidrug Antibodies and Drug Development: Challenges in the Immunotherapy Era
6个月前
已完结
A Novel Neutralization Antibody Assay Method to Overcome Drug Interference with Better Compatibility with Acid-Sensitive Neutralizing Antibodies
6个月前
已完结
A Novel Neutralization Antibody Assay Method to Overcome Drug Interference with Better Compatibility with Acid-Sensitive Neutralizing Antibodies
6个月前
已完结
Nanobodies from camelid mice and llamas neutralize SARS-CoV-2 variants
6个月前
已完结
Evaluation of atezolizumab immunogenicity: Clinical pharmacology (part 1)
6个月前
已完结
皖公网安备34019202002308
